Showing 3591-3600 of 4063 results for "".
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- More Data Point to Pfizer, BioNTech Vaccine Cutting COVID-19 Transmission Rateshttps://modernod.com/news/more-data-point-to-pfizer-biontech-vaccine-cutting-covid-19-transmission-rates/2478965/Mounting real-world evidence from Israel suggests that Pfizer and BioNTech’s vaccine BNT162b2 can “dramatically” cut incidence rates of COVID-19 disease in fully vaccinated individuals, according to a joint statement issued Thursday by the companies and the Israeli Ministry of H
- Samsara Vision and Medevise Consulting Announce European Partnershiphttps://modernod.com/news/samsara-vision-and-medevise-consulting-announce-european-partnership/2478956/Samsara Vision announced it will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement,
- Survey Suggests People Living With Glaucoma at Increased Risk of Sight Loss and Blindness Due to COVID-19 Pandemichttps://modernod.com/news/survey-suggests-people-living-with-glaucoma-at-increased-risk-of-sight-loss-and-blindness-due-to-covid-19-pandemic/2478946/People with glaucoma have struggled to access their healthcare treatment during the COVID-19 pandemic, putting them at risk of vision loss and blindness, according to results of a new European survey of 2,010 adults with glaucoma, including 250 UK respondents.* The survey is part of a mult
- Envision Announces Call for Applications for Next Class of Research Fellowshttps://modernod.com/news/envision-announces-call-for-applications-for-next-class-of-research-fellows/2478919/Envision announced that it has created two new research fellowship opportunities to be carried out through the Gigi & Carl Allen Envision Research Institute (ERI) in Wichita. Selected projects will start between April through the end of Summer 2021. Established in 2015, the Envision Re
- Remembering Ophthalmic Industry Executive George Marcellinohttps://modernod.com/news/remembering-george-marcellino-vice-president-of-marketing-and-clinical-affairs/2478916/Ophthalmic industry executive George Marcellino, PhD, whose work lead to the development of several new technologies and medical devices, died on February 10, 2021. Most recently, Dr. Marcellino served as vice president of clinical affairs and marketing at Iridex. On its website, Iridex posted th
- Allergan Submits New Drug Application for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-submits-new-drug-application-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478915/Allergan announced that it has submitted a new drug application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021. The NDA is based primarily on data from two phase 3 G
- New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phasehttps://modernod.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (activ
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- PYC Therapeutics Accelerates Its Pipeline of RNA Therapeutics for Ocular Diseaseshttps://modernod.com/news/pyc-therapeutics-accelerates-its-pipeline-of-rna-therapeutics-for-ocular-diseases/2478892/PYC Therapeutics announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. “This year we are focused on transforming PYC Therapeutics into a U.S.-bas